Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heplisav-B in immunosuppressed patients
NCT04199715Phase 1Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by Baylor Scott & White Research Institute. Primary endpoints: Safety of Heplisav-B Vaccine at 60 weeks and Immunologic Efficacy of Heplisav-B Vaccine at 60 weeks. Started Dec 2019; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04199715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199715.